Clinical Trial Halt Sends Intellia Shares into a Tailspin

Intellia Therapeutics faces a pivotal juncture as the market anticipates its upcoming quarterly earnings release. The biotech firm’s stock remains under intense pressure following a devastating clinical hold imposed by the U.S. Food and Drug Administration. This regulatory action triggered a massive sell-off, erasing nearly half of the company’s market value at its lowest point.

The crisis unfolded rapidly in late October. Intellia first voluntarily paused patient enrollment in its crucial Phase 3 studies, MAGNITUDE and MAGNITUDE-2, on October 27. This decision came after a participant receiving treatment was hospitalized with serious liver complications. Merely two days later, the FDA formalized this pause into a complete clinical hold.

The Read more...